References
- Petejova N, Martinek A. Renal cell carcinoma: review of etiology, pathophysiology and risk factors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(2):183–194.
- Gul A, Rini BI. Adjuvant therapy in renal cell carcinoma. Cancer. 2019;125(17):2935–2944.
- Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477–2490.
- Cairns P. Renal cell carcinoma. Cancer Biomark. 2010;9(1–6):461–473.
- Belldegrun AS, Klatte T, Shuch B, et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer. 2008;113(9):2457–2463.
- May MB, Glode A. Novel uses for lipid-lowering agents. J Adv Pract Oncol. 2016;7(2):181–187.
- Sopkova J, Vidomanova E, Strnadel J, et al. The role of statins as therapeutic agents in cancer. Gen Physiol Biophys. 2017;36(5):501–511.
- Zaleska M, Mozenska O, Bil J. Statins use and cancer: an update. Future Oncol. 2018;14(15):1497–1509.
- Dai TY, Cao L, Yang ZC, et al. P68 RNA helicase as a molecular target for cancer therapy. J Exp Clin Cancer Res. 2014;33:64.
- Lane DP, Hoeffler WK. SV40 large T shares an antigenic determinant with a cellular protein of molecular weight 68,000. Nature. 1980;288(5787):167–170.
- Li MY, Liu JQ, Chen DP, et al. p68 prompts the epithelial-mesenchymal transition in cervical cancer cells by transcriptionally activating the TGF-β1 signaling pathway . Oncol Lett. 2018;15(2):2111–2116.
- Hashemi V, Masjedi A, Hazhir-Karzar B, et al. The role of DEAD-box RNA helicase p68 (DDX5) in the development and treatment of breast cancer. J Cell Physiol. 2019;234(5):5478–5487.
- Fuller-Pace FV, Moore HC. RNA helicases p68 and p72: multifunctional proteins with important implications for cancer development. Future Oncol. 2011;7(2):239–251.
- Wang R, Bao HB, Du WZ, et al. P68 RNA helicase promotes invasion of glioma cells through negatively regulating DUSP5. Cancer Sci. 2019;110(1):107–117.
- Prabhakar S, Asuthkar S, Lee W, et al. Targeting DUSPs in glioblastomas - wielding a double-edged sword? Cell Biol Int. 2014;38(2):145–153.
- Kutty RG, Talipov MR, Bongard RD, et al. Dual specificity phosphatase 5-substrate interaction: a mechanistic perspective. Compr Physiol. 2017;7(4):1449–1461.
- Lai Y, Zeng T, Liang X, et al. Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy. Cancer Cell Int. 2019;19:221.
- Angulo JC, Shapiro O. The changing therapeutic landscape of metastatic renal cancer. Cancers. 2019;11(9):1227.
- Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–2385.
- Davies JT, Delfino SF, Feinberg CE, et al. Current and emerging uses of statins in clinical therapeutics: a review. Lipid Insights. 2016;9:13–29.
- Denoyelle C, Vasse M, Korner M, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001;22(8):1139–1148.
- Ahern TP, Pedersen L, Tarp M, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103(19):1461–1468.
- Sendur MA, Aksoy S, Yazici O, et al. Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer. Med Oncol. 2014;31(2):835.
- Wang A, Aragaki AK, Tang JY, et al. Statin use and all-cancer survival: prospective results from the Women’s Health Initiative. Br J Cancer. 2016;115(1):129–135.
- Longo J, van Leeuwen JE, Elbaz M, et al. Statins as anticancer agents in the era of precision medicine. Clin Cancer Res. 2020;26(22):5791–5800.
- Likus W, Siemianowicz K, Bieńk K, et al. Could drugs inhibiting the mevalonate pathway also target cancer stem cells? Drug Resist Updat. 2016;25:13–25.